Radioimmunotherapy.org: A web 2.0-based online community

Learning Objectives Radioimmunotherapy.org is a Web2.0-based community tool for radioimmunotherapy researchers, physicians, treatment centers, patients and the the general population.

Summary: Radioimmunotherapy (RIT) with Bexxar™ and Zevalin™ shows high efficacy and has been approved by the FDA. Further Radioimmunotherapeuticals are under investigation and show promising results. However, despite the very promising clinical and preclinical results of Radioimmunotherapy, it is rarely used. The reason for this underuse is unclear but lies probably in the low perception of RIT in the medical society, the medical governance, by patients and in the general population. Web2.0-based online communities are a fast growing entity. Websites such as LinkedIn.com™ or Xing.com™ are widely used business communication tools that enhance business activities or increase personal connections. We hypothesize that a Web2.0-based community tool exclusively for Radioimmunotherapy would be of benefit to Nuclear Medicine Society, researchers, physicians, patients and the general population. We created Radioimmunotherapy.org, a Web2.0-based, free online community, accessible to patients, researchers, physicians, Radioimmunotherapy treatment centers, research centers and the pharmaceutical industry. Our goal is to use a Web2.0-like community to establish connections between researchers and interested subjects, treatment centers or physicians for the industry to reference new products or clinical trials or simply to spread the thought of Radioimmunotherapy. Overall, Radioimmunotherapy.org might be a tool to improve the acceptance of Radioimmunotherapy, in general.